蓬莱诺康

Penglai Nuokang Pharmaceutical is a specialized biopharmaceutical company based in China, primarily focused on the research, development, and production of hemostatic agents. The company is a leading manufacturer of snake venom-derived proteins, most notably Hemocoagulase Agkistrodon, marketed under the brand name Suling. This flagship product is a domestic Class 1 new drug in China, widely utilized in clinical settings to prevent and treat surgical bleeding. Penglai Nuokang operates as a core subsidiary of Nuokang Biopharma, which was acquired by SciClone Pharmaceuticals in 2023 to strengthen its perioperative product portfolio. The company maintains high-standard GMP manufacturing facilities dedicated to biochemical extraction and sterile preparation. Its business model integrates specialized biological manufacturing with a focus on the hematology and surgical markets.